Hepatitis C Market Forecast 2032: FDA, EMA, PDMA Approvals, Epidemiology, Therapies, Clinical Trials and Companies by DelveInsight | BMS, Merck, Roche, Gilead Sciences, Johnson & Johnson, Abbvie
https://www.theglobeandmail.com/investing/markets/markets-news/GetNews/26038163/hepatitis-c-market-forecast-2032-fda-ema-pdma-approvals-epidemiology-therapies-clinical-trials-and-companies-by-delveinsight-bms-merck-roche-gilead-sciences-johnson-johnson-abbvie/
$10 Billion Deal, page-12434
-
- There are more pages in this discussion • 834 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add BIT (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
3.0¢ |
Change
-0.003(9.09%) |
Mkt cap ! $27.06M | |||
| Open | High | Low | Value | Volume |
| 3.3¢ | 3.4¢ | 3.0¢ | $32.26K | 1.016M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 14 | 720804 | 3.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 3.1¢ | 30000 | 1 |
View Market Depth
| Last trade - 16.10pm 25/07/2024 (20 minute delay) ? |
| BIT (ASX) Chart |